Claims for Patent: 7,064,243

Summary for Patent: 7,064,243

Title:	Screens and assays for agents useful in controlling parasitic nematodes
Abstract:	The invention provides a method of identifying anti-nematode compounds and further provides transgenic nematodes that may be used to practice the method. In particular, the invention provides a screen for compounds that inhibit a nematode secretion pathway e.g, compounds that inhibit the secretion of proteins by nematodes. The transgenic nematodes express reporters for nematode secreted proteins. In preferred embodiments of the invention the screen is performed using C. elegans, i.e., certain embodiments of the invention utilize C. elegans and C. elegans secretory pathways as a model system for parasitic nematodes and parasitic nematode secretion pathways. The invention also provides pharmaceutical compositions that may be used in the treatment and prevention of nematode infection in humans and animals and anti-nematode agents that may be used to protect plants from plant-parasitic nematodes. In addition, the invention provides a genetic screen for identifying additional targets for anti-nematode compounds.
Inventor(s):	Liu; Leo (Weston, MA), Burnam; Lucinda (Somerville, MA), Sluder; Ann (Burlington, MA), Link; Elizabeth (Brentwood, TN), Westlund; Beth (Brookline, MA)
Assignee:	Cambria Biosciences LLC (Bedford, MA)
Application Number:	10/051,644
Patent Claims:	1. A transgenic C. elegans nematode, the cells of which contain a transgene comprising a regulatory element of the C. elegans vap-1 gene operably linked to a DNA sequence encoding a detectable marker, wherein the detectable marker is expressed in a C. elegans amphid sheath cell. 2. The transgenic nematode of claim 1, wherein the transgene further comprises at least a portion of the coding sequence of the C. elegans vap-1 gene. 3. The transgenic nematode of claim 2, wherein the transgene further comprises at least a portion of an intron from the C. elegans vap-1 gene. 4. The transgenic nematode of claim 2, wherein the transgene further comprises at least a portion of the 3' untranslated region from the C. elegans vap-1 gene. 5. The transgenic nematode of claim 2, wherein the coding sequence of the C. elegans vap-1 gene is in frame with the sequence encoding the detectable marker. 6. The transgenic nematode of claim 1, wherein the transgene is contained in a chromosome. 7. The transgenic nematode of claim 1, wherein the transgene is extrachromosomal. 8. The transgenic nematode of claim 5, wherein the transgene comprises an integrated array comprising a second regulatory element operably linked to a second copy of a DNA sequence encoding the detectable marker. 9. The transgenic nematode of claim 8, wherein the second regulatory element directs expression of the detectable marker in a substantially different population of cells to that in which the regulatory element of the C. elegans vap-1 gene directs expression of the detectable marker. 10. The transgenic nematode of claim 1, wherein the detectable marker is selected from the list consisting of: a fluorescent polypeptide, a chemiluminescent polypeptide, an epitope tag, and an enzyme. 11. The transgenic nematode of claim 1, wherein the detectable marker is selected from the list consisting of: green fluorescent protein, luciferase, chloramphenicol acetyl transferase, xanthine-guanine phosphoribosyl transferase, beta-galactosidase, horseradish peroxidase, alkaline phosphatase, a Myc tag, and an HA tag. 12. The transgenic nematode of claim 1, wherein the detectable marker comprises a variant of a marker selected from the list consisting of: green fluorescent protein, luciferase, chloramphenicol acetyl transferase, xanthine-guanine phosphoribosyl transferase, beta-galactosidase, horseradish peroxidase, alkaline phosphatase, a Myc tag, and an HA tag, wherein the variant is detectable using the same detection means by which the marker of which it is a variant is detectable. 13. The transgenic nematode of claim 1, wherein the regulatory element comprises a 5' regulatory region extending up to 10 kB in a 5' direction from the start codon of the C. elegans vap-1 gene. 14. A method of generating a nematode comprising steps of: (a) selecting a parasitic nematode secretory protein; (b) identifying a C. elegans homolog of the protein selected in step (a); (c) identifying a nucleic acid sequence comprising a regulatory region of a C. elegans gene encoding the C. elegans homolog identified in step (b); and (d) generating a transgenic C. elegans nematode, wherein cells of the transgenic nematode comprise a nucleic acid sequence including the identified regulatory region operably linked to a nucleic acid sequence encoding a detectable marker, wherein the regulatory region directs expression in a pharyngeal gland cell or amphid sheath cell and the detectable marker is expressed in a pharyngeal gland cell or amphid sheath cell. 15. The method of claim 14, wherein the parasitic nematode is a member of an order selected from the group consisting of the Strongylida, Rhabditida, Ascaridida, Spirurida, Oxyurida, Enoplida, Tylenchida, or Dorylaimida nematode orders. 16. The method of claim 14, wherein the regulatory region comprises a promoter of the C. elegans homolog identified in step (b). 17. The method of claim 14, wherein the nucleic acid sequence of step (d) includes at least a portion of the coding sequence of a gene encoding the C. elegans homolog of part (c). 18. The method of claim 17, wherein the nucleic acid sequence of step (d) includes a signal sequence. 19. The method of claim 17, wherein the nucleic acid sequence of step (d) includes at least a portion of an intron from a gene encoding the C. elegans homolog of part (c). 20. The method of claim 17, wherein the nucleic acid sequence of step (d) includes at least a portion of the 3' untranslated region from a gene encoding the C. elegans homolog of part (c). 21. The method of claim 14, wherein the regulatory region is sufficient to direct expression of the nucleic acid of step (d). 22. The method of claim 14, wherein the parasitic nematode is a member of a genus selected from the list consisting of the Haemonchus, Oestertagia, Trichostrongylus, Cooperia, Dictyocaulus, Strongylus, Oesophagostomum, Syngamus, Nematodirus, Heligmosomoides, Nippostrongylus, Metastrongylus, Angiostrongylus, Ancylostoma, Necator, Uncinaria, Bunostomum, Strongyloides, Steinernema, Ascaris, Parascaris, Toxocara, Toxascaris, Baylisascaris, Anisakis, Pseudoterranova, Heterakis, Wuchereria, Brugia, Onchocerca, Dirofilaria, Loa, Thelazia, Dracunculus, Gnathostoma, Enterobius, Oxyuris, Syphacia, Trichinella, Trichuris, Capillaria, Globodera, Heterodera, Meloidogyne, Anguina, Ditylenchus, Hirschmanniella, Naccobus, Pratylenchus, Radopholus, Criconema, Tylenchulus, Paratylenchus, Aphelenchus, Bursaphelenchus, Longidorus, Xiphinema, Trichodorus, and Paratrichodorus nematode genera. 23. A method of expressing a polynucleotide in a C. elegans nematode comprising the step of: generating a transgenie C. elegans nematode, cells of which comprise a transgene comprising a C. elegans vap-1 regulatory region operably linked to the polynucleotide; and maintaining the C. elegans nematode so that expression of the first polynucleotide occurs in an amphid sheath cell. 24. The method of claim 23, wherein the polynucleotide encodes a polypeptide. 25. The method of claim 23, wherein the transgene comprises a sequence extending in a 5' up to 10 kB direction from the start codon of the C. elegans vap-1 gene. 26. The method of claim 23, wherein the generating step comprises injecting a polynucleotide into a C. elegans nematode, wherein the polynucleotide comprises a C. elegans vap-1 regulatory region operably linked to the polynucleotide. 27. The method of claim 23, wherein the polynucleotide encodes a detectable marker. 28. The method of claim 27, wherein the detectable marker is selected from the list consisting of: a fluorescent polypoptide, a chemiluminsecent polypeptide, an epitope tag, and an enzyme. 29. The method of claim 27, wherein the detectable marker is selected from the list consisting of: green fluorescent protein, luciferase, ehloraxnphenicol acetyl transferase, xanthine-guanine phosphoribosyl transferase, beta-galactosidase, horseradish peroxidose, alkaline phosphates; a Myc tag, and an HA tag. 30. The method of claim 27, wherein the detectable marker comprises a variant of a marker selected from the list consisting of: green fluorescent protein, luciferase, chloramphenicol acetyl transferase, xanthine-guanine phosphoribosyl transferase, beta-galactosidase, horseradish peroxidase, alkaline phosphatase, horseradish peroxidase, alkaline phosphatase, a Myc tag, and an HA tag, wherein the variant is detectable using the some detection means by which the marker of which it is a variant is detectable. 31. The method of claim 27, wherein the detectable marker is alkaline phosphatase. 32. The method of claim 23, wherein the transgene further comprises at least a portion of the coding sequence of the C. elegans vap-1 gene, at least a portion of an intron of the C. elegans vap-1 gene, at least a portion of the 3' untranslated region of the C. elegans vap-1 gene, or any combination of the foregoing.

Details for Patent 7,064,243

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2021-01-18
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2021-01-18
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2021-01-18